Indications
Saxagliptin is indicated for the treatment of type 2 diabetes mellitus. It is used to enhance glycemic control and can be administered either as monotherapy or in combination with other antidiabetic agents. Through its mechanism of action, saxagliptin offers a therapeutic option for managing blood glucose levels in patients with type 2 diabetes.
Pharmacodynamics
The pharmacodynamic profile of saxagliptin is characterized by a significant increase in the levels of incretin hormones GLP-1 and GIP, by two- to three-fold, following administration. Saxagliptin's high selectivity for DPP-4 inhibition results in minimized systemic side effects. This inhibition is sustained over a 24-hour period, leading to decreased glucagon concentrations and enhanced insulin secretion from pancreatic beta cells in a glucose-dependent manner. The compound has a half-maximal inhibitory concentration (IC50) of 0.5 nmol/L and does not extend the QTc interval to a clinically relevant extent.
Absorption
After the oral administration of a 5 mg single dose of saxagliptin to healthy individuals, the mean area under the concentration-time curve (AUC) values for saxagliptin and its active metabolite are 78 ng·h/mL and 214 ng·h/mL, respectively. The peak plasma concentrations (Cmax) recorded were 24 ng/mL for saxagliptin and 47 ng/mL for its metabolite, occurring at median times (Tmax) of 2 hours and 4 hours, respectively. Saxagliptin displays a bioavailability of 67% across doses ranging from 2.5 to 50 mg and does not exhibit accumulation with repeated dosing.
Metabolism
Saxagliptin undergoes extensive hepatic metabolism, primarily via the cytochrome P450 3A4/5 (CYP3A4/5) enzyme system. About 50% of the absorbed dose is metabolized in the liver. The key metabolite, 5-hydroxy saxagliptin, retains DPP-4 inhibitory activity but is only half as potent as the parent compound. This metabolic process contributes to saxagliptin's overall therapeutic effect in managing type 2 diabetes.
Mechanism of Action
Saxagliptin operates as an antidiabetic agent by serving as a dipeptidyl peptidase-4 (DPP-4) inhibitor, offering therapeutic benefits for individuals with type 2 diabetes. This class of compounds acts by modulating the activity of incretin hormones, which play a crucial role in regulating blood glucose levels. Incretins function by enhancing insulin secretion from the pancreas and suppressing hepatic glucose production, thus lowering blood sugar levels. DPP-4, a membrane-associated enzyme found in various tissues as well as in lymphocytes and plasma, facilitates two primary mechanisms: an enzymatic function and a signaling role via adenosine deaminase binding. Saxagliptin exerts its effects by forming a reversible, histidine-assisted covalent bond with the S630 hydroxyl oxygen of DPP-4 through its nitrile group. This inhibition of DPP-4 leads to an increase in active glucagon-like peptide-1 (GLP-1) levels, which subsequently decreases glucagon release from pancreatic alpha cells while promoting insulin synthesis from pancreatic beta cells.
